Technical Analysis for APLT - Applied Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical APLT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.08% | |
| Wide Bands | Range Expansion | 1.08% | |
| Oversold Stochastic | Weakness | 1.08% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 22 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
| Rose Above 10 DMA | about 22 hours ago |
| Outside Day | about 22 hours ago |
| Down 1% | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Myopathy Retinopathy Cardiomyopathy Preclinical Stage Product Stage Products Novel Products Diabetic Peripheral Neuropathy Lactose Peripheral Neuropathy Preclinical Stage Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Myopathy Retinopathy Cardiomyopathy Preclinical Stage Product Stage Products Novel Products Diabetic Peripheral Neuropathy Lactose Peripheral Neuropathy Preclinical Stage Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 51.99 |
| 52 Week Low | 13.58 |
| Average Volume | 134,143 |
| 200-Day Moving Average | 22.59 |
| 50-Day Moving Average | 20.40 |
| 20-Day Moving Average | 18.25 |
| 10-Day Moving Average | 16.88 |
| Average True Range | 1.32 |
| ADX | 13.89 |
| +DI | 16.36 |
| -DI | 20.52 |
| Chandelier Exit (Long, 3 ATRs ) | 18.61 |
| Chandelier Exit (Short, 3 ATRs ) | 20.07 |
| Upper Bollinger Band | 21.34 |
| Lower Bollinger Band | 15.16 |
| Percent B (%b) | 0.26 |
| BandWidth | 33.85 |
| MACD Line | -1.02 |
| MACD Signal Line | -0.96 |
| MACD Histogram | -0.0618 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.59 | ||||
| Resistance 3 (R3) | 18.64 | 18.08 | 18.29 | ||
| Resistance 2 (R2) | 18.08 | 17.62 | 18.06 | 18.19 | |
| Resistance 1 (R1) | 17.44 | 17.34 | 17.76 | 17.39 | 18.09 |
| Pivot Point | 16.88 | 16.88 | 17.05 | 16.86 | 16.88 |
| Support 1 (S1) | 16.24 | 16.42 | 16.56 | 16.19 | 15.49 |
| Support 2 (S2) | 15.68 | 16.14 | 15.66 | 15.39 | |
| Support 3 (S3) | 15.04 | 15.68 | 15.29 | ||
| Support 4 (S4) | 14.99 |
